Stay updated on Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error page instead of the study record content. This indicates that access to the record is blocked, rather than representing a substantive update to the study details.
    Difference
    18%
    Check dated 2026-09-24T18:40:14.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    The page shows a new revision version (v3.7.0) replacing the previous v3.6.6, indicating an update to the page’s revision metadata. This appears to be a general update rather than a substantive change to the study content or eligibility details.
    Difference
    0.0%
    Check dated 2026-09-17T22:45:47.000Z thumbnail image
  3. Check
    16 days ago
    No Change Detected
  4. Check
    23 days ago
    Change Detected
    Summary
    The study's locations list was updated to reflect fewer active sites: the page now shows 39 locations, and several previously listed sites (e.g., Busan, Michalovce, Cebu, San Luis Potosí City, Mexico City, and other Mexican sites) were removed.
    Difference
    0.6%
    Check dated 2026-09-03T22:18:42.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The page's revision label was updated from v3.6.5 to v3.6.6, indicating a minor version update. This update does not modify the study details or listed locations.
    Difference
    0.0%
    Check dated 2026-08-27T19:51:34.000Z thumbnail image
  6. Check
    58 days ago
    Change Detected
    Summary
    The study expanded its locations to 44 sites across multiple countries, adding Busan (South Korea), Michalovce (Slovakia), Cebu (Philippines), San Luis Potosí City (Mexico), and Mexico City (Mexico). This broadens geographic participation and potential enrollment for the trial.
    Difference
    0.6%
    Check dated 2026-07-30T14:33:00.000Z thumbnail image
  7. Check
    65 days ago
    Change Detected
    Summary
    The page revision tag was updated from v3.6.3 to v3.6.4, signaling a new version of the page. This update appears to reflect behind-the-scenes maintenance rather than changes to study details.
    Difference
    0.0%
    Check dated 2026-07-23T09:47:27.000Z thumbnail image

Stay in the know with updates to Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Combo Immunotherapies vs Pembrolizumab in NSCLC Clinical Trial page.